Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study.
Castillo-Mancilla JR, Phillips AN, Neaton JD, Neuhaus J, Sharma S, Baker JV, Collins S, Mannheimer S, Pett S, Touzeau-Römer V, Polizzotto MN, Lundgren JD, Gardner EM; INSIGHT START Study Group. Castillo-Mancilla JR, et al. Among authors: sharma s. J Int AIDS Soc. 2019 Jun;22(6):e25297. doi: 10.1002/jia2.25297. J Int AIDS Soc. 2019. PMID: 31250552 Free PMC article. Clinical Trial.
Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.
Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, MacArthur RD, Chesney M, Friedland G, Mannheimer SB; Terry Beirn Community Programs for Clinical Research on AIDS and the International Network for Strategic Initiatives in Global HIV Trials. Gardner EM, et al. Among authors: sharma s. AIDS. 2010 Jan 28;24(3):395-403. doi: 10.1097/qad.0b013e328335cd8a. AIDS. 2010. PMID: 20099399 Free PMC article. Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. INSIGHT START Study Group, et al. Among authors: sharma s. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. N Engl J Med. 2015. PMID: 26192873 Free PMC article. Clinical Trial.
The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.
Lodi S, Sharma S, Lundgren JD, Phillips AN, Cole SR, Logan R, Agan BK, Babiker A, Klinker H, Chu H, Law M, Neaton JD, Hernán MA; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) study group. Lodi S, et al. Among authors: sharma s. AIDS. 2016 Nov 13;30(17):2659-2663. doi: 10.1097/QAD.0000000000001243. AIDS. 2016. PMID: 27782964 Free PMC article. Clinical Trial.
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.
Baker JV, Sharma S, Achhra AC, Bernardino JI, Bogner JR, Duprez D, Emery S, Gazzard B, Gordin J, Grandits G, Phillips AN, Schwarze S, Soliman EZ, Spector SA, Tambussi G, Lundgren J; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group. Baker JV, et al. Among authors: sharma s. J Am Heart Assoc. 2017 May 22;6(5):e004987. doi: 10.1161/JAHA.116.004987. J Am Heart Assoc. 2017. PMID: 28533305 Free PMC article. Clinical Trial.
Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study.
Ronit A, Sharma S, Baker JV, Mngqibisa R, Delory T, Caldeira L, Ndembi N, Lundgren JD, Phillips AN; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Treatment (START) Study Group. Ronit A, et al. Among authors: sharma s. J Infect Dis. 2018 Jan 17;217(3):405-412. doi: 10.1093/infdis/jix350. J Infect Dis. 2018. PMID: 29244111 Free PMC article. Clinical Trial.
Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.
Baker JV, Sharma S, Grund B, Rupert A, Metcalf JA, Schechter M, Munderi P, Aho I, Emery S, Babiker A, Phillips A, Lundgren JD, Neaton JD, Lane HC; INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group. Baker JV, et al. Among authors: sharma s. Open Forum Infect Dis. 2017 Nov 28;4(4):ofx262. doi: 10.1093/ofid/ofx262. eCollection 2017 Fall. Open Forum Infect Dis. 2017. PMID: 29308409 Free PMC article.
25,295 results
You have reached the last available page of results. Please see the User Guide for more information.